Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 3Myeloid 1

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

fludarabine 33Specimen Handling 32Azacitidine 31venetoclax 30Cyclophosphamide 29Biopsy 25fludarabine phosphate 23Whole-Body Irradiation 19Cytarabine 19ruxolitinib 18Mycophenolic Acid 18Busulfan 18Tacrolimus 16asciminib 15Melphalan 14Injections 14Decitabine 14X-Rays 12Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 12decitabine and cedazuridine drug combination 11Magnetic Resonance Spectroscopy 11Cyclosporine 11Sirolimus 10Peripheral Blood Stem Cell Transplantation 10Thiotepa 9Filgrastim 9nilotinib 7Methotrexate 7Imatinib Mesylate 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medrol Veriderm × Myeloid × 90 days × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡